Effects of Previous Infection, Vaccination, and Hybrid Immunity Against Symptomatic Alpha, Beta, and Delta SARS-CoV-2 Infections: an Observational Study

Background: Protection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination were investigated in Qatar for the Alpha, Beta, and Delta variants.

Methods: Six national, matched, test-negative, case-control studies were conducted between January 18 and December 18, 2021 on a sample of 239,120 PCR-positive tests and 6,103,365 PCR-negative tests.

Findings: Effectiveness of previous infection against Alpha, Beta, and Delta reinfection was 89.5% (95% CI: 85.5-92.3%), 87.9% (95% CI: 85.4-89.9%), and 90.0% (95% CI: 86.7-92.5%), respectively. Effectiveness of two-dose BNT162b2 vaccination against Alpha, Beta, and Delta infection was 90.5% (95% CI, 83.9-94.4%), 80.5% (95% CI: 79.0-82.0%), and 58.1% (95% CI: 54.6-61.3%), respectively. Effectiveness of three-dose BNT162b2 vaccination against Delta infection was 91.7% (95% CI: 87.1-94.7%). Effectiveness of hybrid immunity of previous infection and two-dose BNT162b2 vaccination was 97.4% (95% CI: 95.4-98.5%) against Beta infection and 94.5% (95% CI: 92.8-95.8%) against Delta infection. Effectiveness of previous infection and three-dose BNT162b2 vaccination was 98.1% (95% CI: 85.7-99.7%) against Delta infection. All five forms of immunity had >90% protection against severe, critical, or fatal COVID-19 regardless of variant. Similar effectiveness estimates were observed for mRNA-1273. A mathematical model accurately predicted hybrid immunity protection by assuming that the individual effects of previous infection and vaccination acted independently.

Interpretation: Hybrid immunity, offering the strongest protection, was mathematically predicted by assuming that the immunities obtained from previous infection and vaccination act independently, without synergy or redundancy.

Funding: The Biomedical Research Program and the Biostatistics, Epidemiology, and the Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, Ministry of Public Health, Hamad Medical Corporation, Sidra Medicine, Qatar Genome Programme, Qatar University Biomedical Research Center, and Qatar University Internal Grant ID QUCG-CAS-23/24-114.

Citing Articles

Clinical characterisation, treatment outcomes, and case fatality risk of patients with different SARS-CoV-2 variants in Bangladesh.

Afroze F, Begum M, Ahmed T, El Arifeen S, Rahman M, Rahman A J Glob Health. 2025; 14:05009.

PMID: 40057834 PMC: 11191382. DOI: 10.7189/jogh.14.05009.

The Role of Memory T-Cell Mediated Immunity in Long-term COVID-19: Effects of Vaccination Status.

Kurmangaliyeva S, Madenbayeva A, Urazayeva S, Bazargaliyev Y, Kudabayeva K, Kurmangaliyev K Iran J Med Sci. 2025; 50(2):61-68.

PMID: 40026299 PMC: 11870859. DOI: 10.30476/ijms.2024.104003.3744.

Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar.

Chemaitelly H, Ayoub H, Faust J, Coyle P, Tang P, Hasan M BMJ Public Health. 2025; 1(1):e000479.

PMID: 40017867 PMC: 11812731. DOI: 10.1136/bmjph-2023-000479.

Vaccine Effectiveness Among 5- to 17-year-old Individuals with Prior SARS-CoV-2 Infection: An EHR-Based Target Trial Emulation Study from the RECOVER Project.

Chen J, Lei Y, Wu Q, Zhou T, Zhang B, Becich M medRxiv. 2025; .

PMID: 39974088 PMC: 11838676. DOI: 10.1101/2025.02.07.25321814.

Humoral and cell-mediated immune responses to COVID-19 vaccines up to 6 months post three-dose primary series in adults with inborn errors of immunity and their breakthrough infections.

Unninayar D, Falcone E, Chapdelaine H, Vinh D, Top K, Derfalvi B Front Immunol. 2025; 15:1501908.

PMID: 39906736 PMC: 11790575. DOI: 10.3389/fimmu.2024.1501908.

References

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

Abu-Raddad L, Chemaitelly H, Malek J, Ahmed A, Mohamoud Y, Younuskunju S . Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months. Infect Genet Evol. 2020; 88:104684. PMC: 7759339. DOI: 10.1016/j.meegid.2020.104684. View

Abu-Raddad L, Chemaitelly H, Ayoub H, Coyle P, Malek J, Ahmed A . Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. PLoS Med. 2021; 18(12):e1003879. PMC: 8726501. DOI: 10.1371/journal.pmed.1003879. View

Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P, Hasan M . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021; 27(9):1614-1621. DOI: 10.1038/s41591-021-01446-y. View

Koo T, Li M . A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med. 2016; 15(2):155-63. PMC: 4913118. DOI: 10.1016/j.jcm.2016.02.012. View

Abu-Raddad L, Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P . Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021; 28(7). PMC: 8194836. DOI: 10.1093/jtm/taab083. View

Jackson M, Nelson J . The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013; 31(17):2165-8. DOI: 10.1016/j.vaccine.2013.02.053. View

Barateau V, Peyrot L, Saade C, Pozzetto B, Brengel-Pesce K, Elsensohn M . Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. Sci Transl Med. 2023; 15(687):eade0550. DOI: 10.1126/scitranslmed.ade0550. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

10.

Ayoub H, Chemaitelly H, Seedat S, Makhoul M, Al Kanaani Z, Al Khal A . Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. J Glob Health. 2021; 11:05005. PMC: 7897910. DOI: 10.7189/jogh.11.05005. View

11.

Chemaitelly H, Bertollini R, Abu-Raddad L . Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant. N Engl J Med. 2021; 385(27):2585-2586. PMC: 8693689. DOI: 10.1056/NEJMc2110300. View

12.

Abu-Raddad L, Chemaitelly H, Bertollini R . Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2022; 386(11):1091-1093. PMC: 8809505. DOI: 10.1056/NEJMc2119432. View

13.

Alsallaq R, Schiffer J, Longini Jr I, Wald A, Corey L, Abu-Raddad L . Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis. 2010; 37(5):290-7. PMC: 2860045. DOI: 10.1097/OLQ.0b013e3181d3d023. View

14.

Chemaitelly H, Faust J, Krumholz H, Ayoub H, Tang P, Coyle P . Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. Int J Infect Dis. 2023; 136:81-90. DOI: 10.1016/j.ijid.2023.09.005. View

15.

Verani J, Baqui A, Broome C, Cherian T, Cohen C, Farrar J . Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. Vaccine. 2017; 35(25):3295-3302. PMC: 7007298. DOI: 10.1016/j.vaccine.2017.04.037. View

16.

Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C . Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023; 23(5):556-567. PMC: 10014083. DOI: 10.1016/S1473-3099(22)00801-5. View

17.

Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View

18.

Gazit S, Saciuk Y, Perez G, Peretz A, Ben-Tov A, Stuart E . Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. Lancet Microbe. 2023; 4(7):e495-e505. PMC: 10101759. DOI: 10.1016/S2666-5247(23)00103-9. View

19.

Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis J . SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022; 209:112911. PMC: 8824301. DOI: 10.1016/j.envres.2022.112911. View

20.

Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View